September 3, 2025
12,753
109
0.85%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
5:44Now PlayingSupplement manufacturers have capitalized on the explosive popularity of diabetes control and weight loss drugs such as Ozempic, Wegovy and Zepbound by flooding the market with their own pills, powders, drops and patches bearing “GLP-1” branding.
But experts say that while the efficacy of those supplements can vary, none are remotely as effective as the GLP-1 agonist medications semaglutide and tirzepatide, and the lack of regulatory oversight on those supplements makes it hard for consumers to know exactly what they are purchasing and using.
While pharmaceuticals released in the U.S. are legally required to undergo rigorous safety and efficacy testing and must be approved by the FDA, the same rules do not apply to supplements. And supplements can be sold directly through social media apps, with influencers using their platforms to advertise the products.
Sign up for Here's The Deal with Lisa Desjardins
Subscribe for exclusive content in our newsletters
PBS News podcasts
Stream your PBS favorites with the PBS app
Find more from PBS News at
Subscribe to our YouTube channel
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.